Results 201 to 210 of about 84,576 (334)

A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System

Pharmacology Research &Perspectives, Volume 13, Issue 6, December 2025.
ABSTRACT Avacopan, an oral C5a receptor antagonist approved for treating anti‐neutrophil cytoplasmic antibodies (ANCA) associated vasculitis, has established efficacy and short‐term safety from clinical trials, but its post‐marketing adverse events (AEs) in real‐world settings require further characterization.
Guojun Liang, Xiaofang Liu, Mengge Gao, Bo Yang, Yang Song, Qiong Liu   +5 more
wiley   +1 more source

Consideration on Estimating Mean Pulmonary Artery Pressure Using Early Diastolic Pulmonary Regurgitation Velocity

Sonography, Volume 12, Issue 4, Page 425-429, December 2025.
ABSTRACT Estimation of mean pulmonary artery pressure (mPAP) using peak velocity of pulmonary regurgitation (PR) obtained via continuous‐wave Doppler echocardiography has been applied in clinical practice. However, the theoretical basis for this method and whether to include right atrial pressure (RAP) in the calculation vary across reports, with no ...
Yuichi Baba, Yuri Ochi, Daigo Hirakawa, Makoto Okawa, Toru Kubo, Naohito Yamasaki, Hiroaki Kitaoka   +6 more
wiley   +1 more source

Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review

British Journal of Pharmacology, Volume 182, Issue 23, Page 5706-5733, December 2025.
Pulmonary arterial hypertension (PAH) is a progressive and life‐threatening disease with limited treatment options. Sex differences are apparent in PAH, specifically in the pathophysiology, prognoses and pharmacological responses of patients. Inflammation and its resolution, which often differ between sexes, are dysregulated in chronic inflammatory ...
Chloe Landy, Miles J. De Blasio, Owen L. Woodman, Pasquale Maffia, Hong Yong Peh, Cheng Xue Qin   +5 more
wiley   +1 more source

Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology

European Respiratory Review, 2010
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two of the key subgroups of pulmonary hypertension. They are characterised by different risk factors.
M. Humbert
doaj  

Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension [PDF]

, 2019
Yu Taniguchi, Xavier Jaïs, Mitja Jevnikar, Athénaïs Boucly, Jason Weatherald, Philippe Brénot, O. Planché, Florence Parent, Laurent Savale, Élie Fadel, David Montani, Marc Humbert, Olivier Sitbon, Gérald Simonneau   +13 more
openalex   +1 more source

Prognostic Value of Antiarrhythmic Drug Suppression of Electrical Storm Prior to Ventricular Tachycardia Ablation

Journal of Cardiovascular Electrophysiology, Volume 36, Issue 12, Page 3310-3320, December 2025.
Kaplan Meir survival curves comparing the elective and urgent groups from time of ablation. Top Left: Long‐term survival. Top Right: VT‐free survival. Bottom Left: ES‐free survival. Bottom Right: Repeat ablation‐free survival. Long term survival was significantly improved in the elective group.
Rafik Issa, Osama El‐Sayed, Mohammed Al‐Sadawi, Muazzum Shah, Kelly Arps, Amrish Deshmukh, Michael Ghannam, Rakesh Latchamsetty, Krit Jongnarangsin, Thomas Crawford, Aman Chugh, Hakan Oral, Fred Morady, Frank Bogun, Jackson J. Liang   +14 more
wiley   +1 more source

Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [PDF]

, 2016
Ryan J. Anderson, Atul Malhotra, Nick H. Kim   +2 more
openalex   +1 more source

Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft

Pacing and Clinical Electrophysiology, Volume 48, Issue 12, Page 1444-1450, December 2025.
ABSTRACT Background The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was ...
Daniel S. Cheah, Kathryn Tsai, Krishna Prasad Kurpad, Yousra Khalid, Sanjay S. Mehta   +4 more
wiley   +1 more source

Incremental value of ePLAR – echocardiographic Pulmonary to Left Atrial Ratio – in the diagnosis of chronic thromboembolic pulmonary hypertension [PDF]

, 2016
Platts, David G., Scalia, Gregory M., Waldie, Anna M.   +2 more
core   +1 more source

P7 Are we screening survivors of pulmonary embolism (PE) for chronic thromboembolic pulmonary hypertension (CTEPH)? [PDF]

, 2011
Maria Wilczynska, Keith M. Taylor
openalex   +1 more source